Produodopa’s positive RWE for Parkinson’s disease to boost clinician confidence in crowded levodopa market, says GlobalData

At the European Academy of Neurology (EAN) 2026 virtual congress, AbbVie presented new 12-month interim data from the ROSSINI study, supporting the real-world safety and effectiveness of Produodopa in patients with advanced Parkinson’s disease. Sustained improvements were observed across motor fluctuations, non-motor symptoms, and selected quality-of-life outcomes. Positive real-world evidence (RWE) for Produodopa could boost […]